Champions Oncology, INC. (CSBR) — SEC Filings

Overview

Champions Oncology, INC. (CSBR) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Dec 15, 2025: CHAMPIONS ONCOLOGY, INC. (CSBR) reported a net income of $237,000 for the three months ended October 31, 2025, a significant decrease from $728,000 in the same period of 2024. For the six months ended October 31, 2025, the company posted a net loss of $230,000, a stark contrast to the net income of

Sentiment Summary

Across 23 filings, the sentiment breakdown is: 1 bullish, 3 bearish, 19 neutral. The dominant filing sentiment for Champions Oncology, INC. is neutral.

Filing Type Overview

Champions Oncology, INC. (CSBR) has filed 10 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 1 SC 13G/A, 1 SC 13D/A, 1 SC 13G with the SEC between Feb 2024 to Mar 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (23)

• 8-K Filing — 8-K · Mar 30, 2026
• Champions Oncology Swings to Six-Month Loss Amid Rising Costs — 10-Q · Dec 15, 2025 Risk: high
  CHAMPIONS ONCOLOGY, INC. (CSBR) reported a net income of $237,000 for the three months ended October 31, 2025, a significant decrease from $728,000 in the same
• Champions Oncology Files 8-K on Security Holder Votes — 8-K · Oct 16, 2025 Risk: low
  Champions Oncology, Inc. filed an 8-K on October 16, 2025, to report on matters submitted to a vote of its security holders. The filing does not contain specifi
• Champions Oncology Swings to Loss Amid Rising R&D Costs — 10-Q · Sep 15, 2025 Risk: high
  CHAMPIONS ONCOLOGY, INC. reported a net loss of $466,000 for the three months ended July 31, 2025, a significant decline from the net income of $1,313,000 in th
• Champions Oncology Sets Oct. 16 Shareholder Meeting, CEO Transition — DEF 14A · Aug 22, 2025 Risk: low
  CHAMPIONS ONCOLOGY, INC. (CSBR) filed a DEF 14A on August 22, 2025, outlining proposals for its Annual Meeting of Stockholders on October 16, 2025. Key proposal
• Champions Oncology's Losses Widen to $10.9M Amid Revenue Growth — 10-K · Jul 23, 2025 Risk: high
  CHAMPIONS ONCOLOGY, INC. reported a net loss of $10.9 million for the fiscal year ended April 30, 2025, a significant increase from the $7.8 million net loss in
• Champions Oncology Files 8-K with Exhibits — 8-K · Jul 21, 2025 Risk: low
  Champions Oncology, Inc. filed an 8-K on July 21, 2025, reporting financial statements and exhibits. The company, previously known as Champions Biotechnology, I
• Champions Oncology Files 10-Q for Q3 2025 — 10-Q · Mar 17, 2025 Risk: low
  Champions Oncology, Inc. filed its 10-Q for the period ending January 31, 2025. The company, previously known as Champions Biotechnology, Inc., is in the biolog
• Champions Oncology Files 8-K on Financials — 8-K · Mar 11, 2025 Risk: low
  Champions Oncology, Inc. filed an 8-K on March 11, 2025, reporting on its results of operations and financial condition. The filing also includes financial stat
• Champions Oncology Files 10-Q for Oct 31, 2024 — 10-Q · Dec 16, 2024 Risk: medium
  Champions Oncology, Inc. filed its 10-Q for the period ending October 31, 2024. The company, previously known as Champions Biotechnology, Inc., is in the biolog
• Champions Oncology Files 8-K on Financials — 8-K · Dec 11, 2024 Risk: low
  On December 11, 2024, Champions Oncology, Inc. filed an 8-K report detailing results of operations and financial condition. The filing includes financial statem
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• Champions Oncology Reports on Shareholder Vote — 8-K · Oct 15, 2024 Risk: low
  Champions Oncology, Inc. filed an 8-K on October 15, 2024, reporting on a matter submitted to a vote of its security holders on October 14, 2024. The company, i
• Champions Oncology Files 8-K: Board and Officer Changes — 8-K · Oct 3, 2024 Risk: medium
  Champions Oncology, Inc. filed an 8-K on October 3, 2024, reporting changes in its board of directors and executive officers, including the election of new dire
• Champions Oncology Files 10-Q — 10-Q · Sep 13, 2024 Risk: low
  Champions Oncology, Inc. filed its 10-Q for the period ending July 31, 2024. The company, previously known as Champions Biotechnology, Inc., is in the biologica
• Champions Oncology Files 8-K on Financials — 8-K · Sep 11, 2024 Risk: low
  Champions Oncology, Inc. filed an 8-K on September 11, 2024, reporting on its results of operations and financial condition. The filing details the company's fi
• Champions Oncology Files Definitive Proxy Statement — DEF 14A · Aug 27, 2024 Risk: low
  Champions Oncology, Inc. filed a Definitive Proxy Statement (DEF 14A) on August 27, 2024. The filing pertains to the company's proxy materials, which are typica
• Champions Oncology Files 2024 10-K — 10-K · Jul 19, 2024 Risk: low
  Champions Oncology, Inc. filed its 10-K for the fiscal year ending April 30, 2024. The company, previously known as Champions Biotechnology, Inc., is involved i
• Champions Oncology Files 8-K on Financials — 8-K · Jul 18, 2024 Risk: low
  Champions Oncology, Inc. filed an 8-K on July 18, 2024, to report on its results of operations and financial condition, as well as to file financial statements
• NEA Group Amends Champions Oncology Stake — SC 13D/A · May 6, 2024 Risk: medium
  New Enterprise Associates 14, L.P. (NEA 14 GP, LTD, NEA PARTNERS 14, L.P.) and associated individuals (Anthony A. Florence, Jr., Forest Baskett, Mohamad Makhzou
• Champions Oncology, Inc. Files 10-Q for Period Ending January 31, 2024 — 10-Q · Mar 15, 2024 Risk: low
  CHAMPIONS ONCOLOGY, INC. (CSBR) filed a Quarterly Report (10-Q) with the SEC on March 15, 2024. Champions Oncology, Inc. filed a 10-Q report for the period endi
• Champions Oncology Files 8-K on Financials — 8-K · Mar 12, 2024 Risk: low
  Champions Oncology, Inc. filed an 8-K on March 12, 2024, reporting on its results of operations and financial condition. The filing includes financial statement
• Tocqueville Asset Mgmt. Discloses 5.0% Stake in Champions Oncology — SC 13G · Feb 12, 2024 Risk: low
  Tocqueville Asset Management L.P. reported on December 28, 2023, that it holds a significant stake in Champions Oncology, Inc. (NASDAQ: CSBR), a company special

Risk Profile

Risk Assessment: Of CSBR's 21 recent filings, 3 were flagged as high-risk, 3 as medium-risk, and 15 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Champions Oncology, INC.'s most recent 10-Q filing (Dec 15, 2025):

• Revenue: $29,030,000
• Net Income: -$230,000
• EPS: -$0.01
• Debt-to-Equity: 6.13
• Cash Position: $8,516,000
• Operating Margin: -1.18%
• Total Assets: $30,162,000
• Total Debt: $18,759,000

Key Executives

• Robert Brainin
• Ronnie Morris, M.D.
• David Miller
• Joel Ackerman
• David Sidransky, M.D.
• Daniel Mendelson
• Scott R. Tobin
• Anthony A. Florence, Jr.
• Forest Baskett
• Mohamad Makhzoumi
• Patrick J. Kerins
• Scott D. Sandell

Industry Context

Champions Oncology operates in the oncology diagnostics and services sector, a field characterized by rapid technological advancements and increasing demand for personalized medicine. The competitive landscape includes established diagnostic companies and emerging biotech firms. Key trends involve the integration of genomic data into clinical decision-making and the development of companion diagnostics.

Top Tags

10-Q (4) · biotechnology (4) · filing (4) · Net Loss (3) · financial-condition (3) · financial-reporting (3) · Oncology (2) · Biotechnology (2) · Liquidity Risk (2) · R&D Spending (2)

Executive Compensation

From the most recent DEF 14A filing (Aug 22, 2025):

• Robert Brainin — Chief Executive Officer
• Dr. Ronnie Morris — Chairman of the Board
• David Miller — Chief Financial Officer

Key Numbers

• Net Loss: $230,000 — For the six months ended October 31, 2025, a significant swing from $2,041,000 net income in 2024.
• Oncology Revenue: $29,030,000 — For the six months ended October 31, 2025, an increase from $27,550,000 in 2024.
• Total Costs and Operating Expenses: $29,372,000 — For the six months ended October 31, 2025, a substantial increase from $25,489,000 in 2024.
• Cash and Cash Equivalents: $8,516,000 — As of October 31, 2025, a decrease from $9,785,000 on April 30, 2025.
• Negative Working Capital: $809,000 — As of October 31, 2025, indicating short-term liquidity challenges.
• Accumulated Deficit: $80,121,000 — As of October 31, 2025, an increase from $79,892,000 on April 30, 2025.
• Research and Development Expenses: $4,698,000 — For the six months ended October 31, 2025, up from $3,143,000 in 2024.
• General and Administrative Expenses: $5,544,000 — For the six months ended October 31, 2025, up from $4,416,000 in 2024.
• Research and Development: $2,082,000 — Increased 43.19% from $1,454,000 in Q1 2024.
• Total Operating Expenses: $14,522,000 — Increased 14.06% from $12,732,000 in Q1 2024.
• Basic Net Loss Per Share: $0.03 — Compared to $0.10 basic net income per share in Q1 2024.
• Shares outstanding: 13,788,421 — As of the Record Date, August 22, 2025, each share is entitled to one vote.
• Annual Meeting Date: October 16, 2025 — Date when stockholders will vote on key proposals.
• Record Date: August 22, 2025 — Date for determining stockholders entitled to vote at the Annual Meeting.
• Approximate Mailing Date: September 3, 2025 — Date for mailing E-Proxy Notices to stockholders.

Forward-Looking Statements

• {"claim":"Champions Oncology's stock price may experience increased stability due to institutional ownership.","entity":"Champions Oncology, Inc.","targetDate":"next 6-12 months","confidence":"medium"}
• {"claim":"Other institutional investors might follow Tocqueville's lead and initiate or increase their positions in Champions Oncology.","entity":"Champions Oncology, Inc.","targetDate":"next 3-6 months","confidence":"low"}

Related Companies

CHMP · CHOS

Frequently Asked Questions